Pheochromocytoma: genes and variants
Explore variant evidence for Pheochromocytoma across 6 analyzed proteins (SDHB, SDHD, RET, VHL, TMEM127 and 1 more). Linked ClinVar records include 71 pathogenic or likely pathogenic variants, 735 variants of uncertain significance and 183 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Pheochromocytoma
SDHB: Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial
It transfers electrons from succinate oxidation through iron-sulfur centers toward ubiquinone in mitochondrial complex II. Heterozygous loss-of-function variants strongly predispose to paraganglioma and pheochromocytoma and can also increase renal-tumor and gastrointestinal-stromal-tumor risk.
47 ClinVar pathogenic / likely pathogenic and 413 uncertain variants in SDHB have source records linked to Pheochromocytoma. Association strength is not clinical gene validity.
SDHD: Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial
It provides a membrane-anchoring component of succinate dehydrogenase and is required for normal complex II electron transfer. Germline loss-of-function variants, often showing a parent-of-origin effect, strongly predispose to head-and-neck paragangliomas and pheochromocytomas.
14 ClinVar pathogenic / likely pathogenic and 221 uncertain variants in SDHD have source records linked to Pheochromocytoma. Association strength is not clinical gene validity.
RET: Proto-oncogene tyrosine-protein kinase receptor Ret
Its activation by GDNF-family ligands guides development of the enteric nervous system, kidney, and other tissues. Activating variants cause multiple endocrine neoplasia type 2 and can drive cancer, whereas loss-of-function variants are an important cause of Hirschsprung disease.
5 ClinVar pathogenic / likely pathogenic and 182 uncertain variants in RET have source records linked to Pheochromocytoma. Association strength is not clinical gene validity.
VHL: von Hippel-Lindau disease tumor suppressor
It targets hydroxylated HIF-alpha proteins for ubiquitin-mediated degradation when oxygen is sufficient, keeping hypoxia-response programs suppressed. Loss of function stabilizes HIF signaling and causes von Hippel-Lindau tumor-predisposition syndrome while also driving most clear-cell renal carcinomas.
4 ClinVar pathogenic / likely pathogenic and 20 uncertain variants in VHL have source records linked to Pheochromocytoma. Association strength is not clinical gene validity.
TMEM127: Transmembrane protein 127
It restrains growth signaling and participates in endomembrane trafficking, including regulation of mTOR-related pathways. Germline loss-of-function variants predispose primarily to pheochromocytoma and paraganglioma and can also occur in selected renal tumors.
1 ClinVar pathogenic / likely pathogenic and 58 uncertain variants in TMEM127 have source records linked to Pheochromocytoma. Association strength is not clinical gene validity.
MAX: Protein max
It forms DNA-binding dimers with MYC-family proteins and other partners, balancing transcriptional programs that promote or restrain proliferation. Germline loss-of-function variants predispose to pheochromocytoma and paraganglioma, while altered MAX-MYC signaling is central to many cancers.
0 ClinVar pathogenic / likely pathogenic and 24 uncertain variants in MAX have source records linked to Pheochromocytoma. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): EPAS1.
Where Pheochromocytoma variants cluster
- SDHD Transmembrane (positions 91–111): 7 of 14 ClinVar pathogenic / likely pathogenic variants, 3.8× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Pheochromocytoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SDHB R46L | 46 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G96S | 96 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G96D | 96 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C196Y | 196 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB R217C | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R217G | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R217L | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R230L | 230 | Pathogenic / likely pathogenic (★★) | |
| SDHB R242C | 242 | Pathogenic / likely pathogenic (★★) | |
| SDHB R242S | 242 | Pathogenic / likely pathogenic (★★) | |
| SDHD D92Y | 92 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHD H102R | 102 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHB R46G | 46 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB D74A | 74 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C98R | 98 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C98Y | 98 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C189Y | 189 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C189F | 189 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB R217S | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R230C | 230 | Pathogenic / likely pathogenic (★★) | |
| SDHD M1I | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHD H102L | 102 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHD H102P | 102 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHD H102Y | 102 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHB M1I | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHB P197R | 197 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB W200R | 200 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C253Y | 253 | Pathogenic / likely pathogenic (★★) | |
| SDHB M1L | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHB M1V | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHB A43P | 43 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C68Y | 68 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C93R | 93 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G99D | 99 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB H132P | 132 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB D138Y | 138 | Pathogenic / likely pathogenic (★★) | |
| SDHB C191Y | 191 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C192Y | 192 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G208R | 208 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB G208E | 208 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB Q214R | 214 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB C243W | 243 | Pathogenic / likely pathogenic (★★) | |
| SDHD M1L | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHD M1V | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHD D92V | 92 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| RET M918T | 918 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| SDHB N248K | 248 | Pathogenic / likely pathogenic (★★) | |
| SDHB L65P | 65 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G69V | 69 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB L87S | 87 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHD G106D | 106 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHD Y114C | 114 | Mitochondrial matrix | Pathogenic / likely pathogenic (★★) |
| RET C620F | 620 | Extracellular | Pathogenic / likely pathogenic (★★) |
| VHL R107G | 107 | Involved in binding to CCT complex | Pathogenic / likely pathogenic (★★) |
| VHL C162Y | 162 | Interaction with Elongin BC complex | Pathogenic / likely pathogenic (★★) |
| RET K424N | 424 | Cadherin-like region 4 (CLD4) | Pathogenic / likely pathogenic (★★) |
| SDHB C189W | 189 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★) |
| SDHB C196R | 196 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★) |
| SDHD M1T | 1 | Pathogenic / likely pathogenic (★) | |
| SDHB C113Y | 113 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★) |
Showing 60 of 71.
Uncertain variants prioritized for review in Pheochromocytoma
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| SDHB W200C | 200 | 4Fe-4S ferredoxin-type | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; W200R at the same position is pathogenic; seen in 6.8e-06 of gnomAD DNA copies; REVEL 0.925 |
| SDHB Q214H | 214 | Interaction with SDHAF1 | Conflicting reports (★) | +7: 5 other pathogenic changes within 3 positions; Q214R at the same position is pathogenic; seen in 6.9e-07 of gnomAD DNA copies; REVEL 0.891 |
| SDHB H132R | 132 | 2Fe-2S ferredoxin-type | Uncertain (★★) | +7: in a 3D region that tolerates change poorly (1R); H132P at the same position is pathogenic; seen in 3.4e-06 of gnomAD DNA copies; REVEL 0.896 |
| SDHB G69S | 69 | 2Fe-2S ferredoxin-type | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; G69V at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.853 |
| SDHB L65F | 65 | 2Fe-2S ferredoxin-type | Uncertain (★★) | +7: 2 other pathogenic changes within 3 positions; L65P at the same position is pathogenic; seen in 3.4e-06 of gnomAD DNA copies; REVEL 0.775 |
| SDHB C192S | 192 | 4Fe-4S ferredoxin-type | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; C192Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB C113G | 113 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; C113S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| SDHB C93F | 93 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; C93R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB G96C | 96 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; G96S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB C189R | 189 | 4Fe-4S ferredoxin-type | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; C189W at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB R217H | 217 | Interaction with SDHAF1 | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; R217S at the same position is pathogenic; REVEL 0.957 |
| SDHB C68R | 68 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; C68Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| SDHB C186R | 186 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; C186Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB C186S | 186 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; C186Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB P197L | 197 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; P197R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| SDHB G99S | 99 | 2Fe-2S ferredoxin-type | Uncertain (★★) | +6: 5 other pathogenic changes within 3 positions; G99D at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| SDHB G96R | 96 | 2Fe-2S ferredoxin-type | Uncertain (★) | +6: 6 other pathogenic changes within 3 positions; G96S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHD D92N | 92 | Transmembrane | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; D92V at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.84 |
| SDHB W200G | 200 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; W200R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.96 |
| SDHD D92E | 92 | Transmembrane | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; D92V at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.90 |
| SDHB D74N | 74 | 2Fe-2S ferredoxin-type | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; D74G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
Which prediction tools work for Pheochromocytoma
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 98 out of 100
- MutPred: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 96 out of 100
- ESM1b (LLR): 96 out of 100
- AlphaMissense: 96 out of 100
- EVE: 96 out of 100
- MetaLR: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 94 out of 100
- PolyPhen-2: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 54 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 36 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Carney-Stratakis syndrome also has ClinVar records linked to SDHB variants; they fall in the same places as the Pheochromocytoma variants (7 pathogenic / likely pathogenic).
- Mitochondrial complex 2 deficiency, nuclear also has ClinVar records linked to SDHB variants; they fall in the same places as the Pheochromocytoma variants (7 pathogenic / likely pathogenic).
- Paragangliomas with sensorineural hearing loss also has ClinVar records linked to SDHD variants; they fall in the same places as the Pheochromocytoma variants (13 pathogenic / likely pathogenic).
- Carney-Stratakis syndrome also has ClinVar records linked to SDHD variants; they fall in the same places as the Pheochromocytoma variants (11 pathogenic / likely pathogenic).
- Cowden syndrome also has ClinVar records linked to SDHD variants; they fall in the same places as the Pheochromocytoma variants (11 pathogenic / likely pathogenic).
- Pheochromocytoma/paraganglioma syndrome also has ClinVar records linked to SDHD variants; they fall in the same places as the Pheochromocytoma variants (4 pathogenic / likely pathogenic).
- Mitochondrial complex 2 deficiency, nuclear also has ClinVar records linked to SDHD variants; they fall in the same places as the Pheochromocytoma variants (3 pathogenic / likely pathogenic).
- Multiple endocrine neoplasia also has ClinVar records linked to RET variants; they fall mostly in different places as the Pheochromocytoma variants (53 pathogenic / likely pathogenic).
- Hirschsprung disease also has ClinVar records linked to RET variants; they fall mostly in different places as the Pheochromocytoma variants (22 pathogenic / likely pathogenic).
- Familial medullary thyroid carcinoma also has ClinVar records linked to RET variants; they fall mostly in different places as the Pheochromocytoma variants (13 pathogenic / likely pathogenic).
- MEN2 phenotype: Unclassified also has ClinVar records linked to RET variants; they fall mostly in different places as the Pheochromocytoma variants (5 pathogenic / likely pathogenic).
- Von Hippel-Lindau disease also has ClinVar records linked to VHL variants; they fall mostly in different places as the Pheochromocytoma variants (147 pathogenic / likely pathogenic).
- Chuvash polycythemia also has ClinVar records linked to VHL variants; they fall mostly in different places as the Pheochromocytoma variants (116 pathogenic / likely pathogenic).
Diseases related to Pheochromocytoma
- Hereditary pheochromocytoma and paraganglioma, also linked to MAX, SDHB, SDHD and TMEM127
- Gastrointestinal stromal tumor, also linked to RET and SDHB
- Pheochromocytoma/paraganglioma syndrome, also linked to SDHB and SDHD
- Carney-Stratakis syndrome, also linked to SDHB and SDHD
- Inherited phaeochromocytoma and paraganglioma excluding NF1, also linked to SDHB and VHL
- Mitochondrial complex 2 deficiency, nuclear, also linked to SDHB and SDHD
- Renal cell carcinoma, also linked to RET and VHL
- Multiple endocrine neoplasia, also linked to RET
- Von Hippel-Lindau disease, also linked to VHL
- Chuvash polycythemia, also linked to VHL
- Cowden syndrome, also linked to SDHD
- Ovarian cancer, also linked to RET
Frequently asked questions
Which genes have records linked to Pheochromocytoma?
This view contains 6 analyzed proteins: SDHB, SDHD, RET, VHL, TMEM127 and 1 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 71 pathogenic or likely pathogenic variants, 735 variants of uncertain significance and 183 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 21 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,065 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center